Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro

Authors: Jun-Wei Liu, Min-Xia Cai, Ying Xin, Qing-Song Wu, Jun Ma, Po Yang, Hai-Yang Xie, Dong-Sheng Huang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

To explore the anti-tumor effects of parthenolide in human pancreatic cancer.

Methods

BxPC-3 cell, a human pancreatic cancer, was treated with parthenolide at different concentrations. The MTT assay was used to analyze cell viability. Flow cytometry and DNA fragmentation analysis were applied to evaluate apoptosis after parthenolide treatment. The wound closure and cell invasion assay were also employed in the study. Western blotting was used to demonstrate Bad, Bcl-2, Bax, caspase-9 and pro-caspase-3 expression.

Results

The MTT assay indicated that the pancreatic cancer growth could be dose-dependently inhibited by parthenoolide. This phenomenon was confirmed by flow cytometry and DNA fragmentation analysis. The wound closure assay and cell invasion assay showed that BxPC-3 cell was significantly suppressed by parthenolide at 7.5 μM and 15 μM. Western Blotting demonstrated the Bcl-2 and pro-caspase-3 were down-regulated while the Bax and caspase-9 were up-regulated. No alteration in Bad expression was found after treatment.

Conclusions

The parthenolide can inhibit the cell growth, migration, and induce the apoptosis in human pancreatic cancer. These findings may provide a novel approach for pancreatic cancer treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA-Cancer J Clin. 2004, 54: 8-29. 10.3322/canjclin.54.1.8.CrossRef Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA-Cancer J Clin. 2004, 54: 8-29. 10.3322/canjclin.54.1.8.CrossRef
2.
go back to reference Safioleas MC, Moulakakis KG: Pancreatic cancer today. Hepatogastroenterology. 2004, 51: 862-868. Safioleas MC, Moulakakis KG: Pancreatic cancer today. Hepatogastroenterology. 2004, 51: 862-868.
3.
go back to reference Pozarowski P, Halicka DH, Parzykiewicz Z: NF-kappaB inhibitor sesquiterpene parthenolide induces concurrently a typical apoptosis and cell necrosis: difficulties in identification of dead cells in such cultures. Cytometry A. 2003, 54: 118-124. 10.1002/cyto.a.10057.CrossRef Pozarowski P, Halicka DH, Parzykiewicz Z: NF-kappaB inhibitor sesquiterpene parthenolide induces concurrently a typical apoptosis and cell necrosis: difficulties in identification of dead cells in such cultures. Cytometry A. 2003, 54: 118-124. 10.1002/cyto.a.10057.CrossRef
4.
go back to reference Zhang S, Ong CN, Shen HM: Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett. 2004, 208: 143-153. 10.1016/j.canlet.2003.11.028.CrossRef Zhang S, Ong CN, Shen HM: Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett. 2004, 208: 143-153. 10.1016/j.canlet.2003.11.028.CrossRef
5.
go back to reference Park JH, Liu L, Kim IH, Kim JH, You KR, Kim DG: Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. Cancer Res. 2005, 65: 2804-2814. 10.1158/0008-5472.CAN-04-2221.CrossRef Park JH, Liu L, Kim IH, Kim JH, You KR, Kim DG: Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. Cancer Res. 2005, 65: 2804-2814. 10.1158/0008-5472.CAN-04-2221.CrossRef
6.
go back to reference Kim JH, Liu L, Lee SO, Kim YT, You KR, Kim DG: Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer Res. 2005, 65: 6312-6320. 10.1158/0008-5472.CAN-04-4193.CrossRef Kim JH, Liu L, Lee SO, Kim YT, You KR, Kim DG: Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer Res. 2005, 65: 6312-6320. 10.1158/0008-5472.CAN-04-4193.CrossRef
7.
go back to reference Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM: Suppressed NF-{kappa}B and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-{alpha}-induced apoptosis in human cancer cells. Carcinogenesis. 2004, 25: 2191-2199. 10.1093/carcin/bgh234.CrossRef Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM: Suppressed NF-{kappa}B and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-{alpha}-induced apoptosis in human cancer cells. Carcinogenesis. 2004, 25: 2191-2199. 10.1093/carcin/bgh234.CrossRef
8.
go back to reference Nakshatri H, Rice SE, Bhat-Nakshatri P: Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene. 2004, 23: 7330-7344. 10.1038/sj.onc.1207995.CrossRef Nakshatri H, Rice SE, Bhat-Nakshatri P: Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene. 2004, 23: 7330-7344. 10.1038/sj.onc.1207995.CrossRef
9.
go back to reference Won YK, Ong CN, Shi X, Shen HM: Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis. 2004, 25: 1449-1458. 10.1093/carcin/bgh151.CrossRef Won YK, Ong CN, Shi X, Shen HM: Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis. 2004, 25: 1449-1458. 10.1093/carcin/bgh151.CrossRef
10.
go back to reference Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM: Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther. 2005, 4: 587-594. 10.1158/1535-7163.MCT-04-0215.CrossRef Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM: Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther. 2005, 4: 587-594. 10.1158/1535-7163.MCT-04-0215.CrossRef
11.
go back to reference Ross JJ, Arnason JT, Birnboim HC: Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med. 1999, 65: 126-129. 10.1055/s-1999-13972.CrossRef Ross JJ, Arnason JT, Birnboim HC: Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med. 1999, 65: 126-129. 10.1055/s-1999-13972.CrossRef
12.
go back to reference Wen J, You KR, Lee SY, Song CH, Kim DG: Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem. 2002, 277: 38954-38964. 10.1074/jbc.M203842200.CrossRef Wen J, You KR, Lee SY, Song CH, Kim DG: Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem. 2002, 277: 38954-38964. 10.1074/jbc.M203842200.CrossRef
13.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRef Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRef
14.
go back to reference Fulda S, Debatin KM: Death receptor signaling in cancer therapy. Curr Med Chem Anti-Canc Agents. 2003, 3: 253-262. 10.2174/1568011033482404.CrossRef Fulda S, Debatin KM: Death receptor signaling in cancer therapy. Curr Med Chem Anti-Canc Agents. 2003, 3: 253-262. 10.2174/1568011033482404.CrossRef
15.
go back to reference Wang W, Abbruzzese JL, Evans DB, Chiao PJ: Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene. 1999, 18: 4554-4563. 10.1038/sj.onc.1202833.CrossRef Wang W, Abbruzzese JL, Evans DB, Chiao PJ: Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene. 1999, 18: 4554-4563. 10.1038/sj.onc.1202833.CrossRef
16.
go back to reference Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM: Stat3 and NF-λB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology. 2002, 123: 2052-2063. 10.1053/gast.2002.37075.CrossRef Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM: Stat3 and NF-λB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology. 2002, 123: 2052-2063. 10.1053/gast.2002.37075.CrossRef
17.
go back to reference Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM: The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkB kinase. Chem Biol. 2001, 8: 759-766. 10.1016/S1074-5521(01)00049-7.CrossRef Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM: The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkB kinase. Chem Biol. 2001, 8: 759-766. 10.1016/S1074-5521(01)00049-7.CrossRef
18.
go back to reference Yip-Schneider MT, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks PA, Neelakantan S, Sweeney CJ, Schmidt CM: Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas. 2008, 37: e45-e53. 10.1097/MPA.0b013e318172b4dd.CrossRef Yip-Schneider MT, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks PA, Neelakantan S, Sweeney CJ, Schmidt CM: Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas. 2008, 37: e45-e53. 10.1097/MPA.0b013e318172b4dd.CrossRef
19.
go back to reference Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM: Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther. 2007, 6: 1736-1744. 10.1158/1535-7163.MCT-06-0794.CrossRef Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM: Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther. 2007, 6: 1736-1744. 10.1158/1535-7163.MCT-06-0794.CrossRef
20.
go back to reference Wang W, Adachi M, Zhang R, Zhou J, Zhu D: A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Pancreas. 2009, 38: e114-e123. 10.1097/MPA.0b013e3181a0b6f2.CrossRef Wang W, Adachi M, Zhang R, Zhou J, Zhu D: A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Pancreas. 2009, 38: e114-e123. 10.1097/MPA.0b013e3181a0b6f2.CrossRef
21.
go back to reference Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 1998, 281: 1322-1326. 10.1126/science.281.5381.1322.CrossRef Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 1998, 281: 1322-1326. 10.1126/science.281.5381.1322.CrossRef
22.
go back to reference Gross A, McDonnell JM, Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Gene Dev. 1999, 13: 1899-1911. 10.1101/gad.13.15.1899.CrossRef Gross A, McDonnell JM, Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Gene Dev. 1999, 13: 1899-1911. 10.1101/gad.13.15.1899.CrossRef
23.
go back to reference Dong M, Zhou JP, Zhang H, Guo KJ, Tian YL, Dong YT: Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. World J G. 2005, 11: 2744-2747. Dong M, Zhou JP, Zhang H, Guo KJ, Tian YL, Dong YT: Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. World J G. 2005, 11: 2744-2747.
24.
go back to reference Wang CY, Guttridge DC, Mayo MW, Baldwin AS: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999, 19: 5923-5929.CrossRef Wang CY, Guttridge DC, Mayo MW, Baldwin AS: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999, 19: 5923-5929.CrossRef
25.
go back to reference Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE: NF-kB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem. 2001, 276: 45380-45386. 10.1074/jbc.M108294200.CrossRef Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE: NF-kB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem. 2001, 276: 45380-45386. 10.1074/jbc.M108294200.CrossRef
26.
go back to reference Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, Bours V: NF-kappa B2/p100 induces Bcl-2 expression. Leukemia. 2003, 17: 1349-1356. 10.1038/sj.leu.2402982.CrossRef Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, Bours V: NF-kappa B2/p100 induces Bcl-2 expression. Leukemia. 2003, 17: 1349-1356. 10.1038/sj.leu.2402982.CrossRef
27.
go back to reference Catz SD, Johnson JL: Transcriptional regulation of Bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001, 20: 7342-7345. 10.1038/sj.onc.1204926.CrossRef Catz SD, Johnson JL: Transcriptional regulation of Bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001, 20: 7342-7345. 10.1038/sj.onc.1204926.CrossRef
28.
go back to reference Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ: Targeting BCL-2 overexpression in various human malignancies through Nf-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmaco1. 2005, 56: 46-54. 10.1007/s00280-004-0944-5.CrossRef Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ: Targeting BCL-2 overexpression in various human malignancies through Nf-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmaco1. 2005, 56: 46-54. 10.1007/s00280-004-0944-5.CrossRef
29.
go back to reference Salvesen GS, Dixit VM: Caspases: mtracellular signaling by proteolysis. Cell. 1997, 91: 443-446. 10.1016/S0092-8674(00)80430-4.CrossRef Salvesen GS, Dixit VM: Caspases: mtracellular signaling by proteolysis. Cell. 1997, 91: 443-446. 10.1016/S0092-8674(00)80430-4.CrossRef
30.
go back to reference Du C, Fang M, Li Y, Wang X, Smac A: Mitochondrial protein that promotes cytochrome-c dependent caspase activation by eliminating IAP inhibition. Cell. 2000, 102: 43-53. 10.1016/S0092-8674(00)00008-8.CrossRef Du C, Fang M, Li Y, Wang X, Smac A: Mitochondrial protein that promotes cytochrome-c dependent caspase activation by eliminating IAP inhibition. Cell. 2000, 102: 43-53. 10.1016/S0092-8674(00)00008-8.CrossRef
31.
go back to reference Zou H, Li Y, Liu X, Wang X: An APAF-1.cytochrome-c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999, 274: 11549-11556. 10.1074/jbc.274.17.11549.CrossRef Zou H, Li Y, Liu X, Wang X: An APAF-1.cytochrome-c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999, 274: 11549-11556. 10.1074/jbc.274.17.11549.CrossRef
Metadata
Title
Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro
Authors
Jun-Wei Liu
Min-Xia Cai
Ying Xin
Qing-Song Wu
Jun Ma
Po Yang
Hai-Yang Xie
Dong-Sheng Huang
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-108

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine